New skin technology for rejuvenation
South Korea is making significant progress in the fight against aging by developing a treatment based on human skin tissue derived from deceased donors. This treatment is known as "Elravie Re2O" or "Back to the Twenties." It utilizes an extracellular matrix containing collagen, elastin, and hyaluronic acid to support skin regeneration and improve its appearance, reducing wrinkles and aging lines. The treatment is still in the regulatory approval stage; it has not yet received approval from the U.S. Food and Drug Administration (FDA), but some American clinics have begun offering it on a limited basis. The goal of the treatment is to rebuild the skin’s structure permanently, rather than providing temporary fillers. It is characterized by a low risk of immune rejection or allergic reactions thanks to the removal of cells from the donor tissue. However, there are potential risks of immune reactions or contamination if the donor screening process is not conducted thoroughly. It is expected to be officially launched in the U.S. market by 2027.
Notice: This Is an AI-Generated Summary
Comments (0)